Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.
| Revenue (TTM) | $36.36B |
| Gross Profit (TTM) | $23.75B |
| EBITDA | $10.10B |
| Operating Margin | 22.10% |
| Return on Equity | 9.84% |
| Return on Assets | 4.92% |
| Revenue/Share (TTM) | $28.37 |
| Book Value | $38.64 |
| Price-to-Book | 2.36 |
| Price-to-Sales (TTM) | 3.23 |
| EV/Revenue | 3.728 |
| EV/EBITDA | 13.82 |
| Quarterly Earnings Growth (YoY) | 18.30% |
| Quarterly Revenue Growth (YoY) | 9.90% |
| Shares Outstanding | $1.28B |
| Float | $1.28B |
| % Insiders | 0.32% |
| % Institutions | 88.68% |
Volatility is currently contracting
Investors looking for stocks in the Medical - Products sector might want to consider either Medtronic (MDT) or Agilent Technologies (A). But which of these two stocks presents investors with the better value opportunity right now?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Medtronic is rated 'Buy' for its compelling combination of income, growth, and value. MDT's growth is led by cardiac ablation with 124% U.S. segment growth and rapid expansion of the Hugo robotic surgery platform. Management guides for 11.75% organic revenue growth in Q1 2027, with CAS expected to outpace the market and Symplicity renal denervation gaining traction.
About a year ago, 24/7 Wall St. flagged four overlooked Dividend Aristocrats as stealth growth plays, arguing that boring income names carried real upside if the market ever noticed.
Sphere-9 all-in-one mapping and ablation, large-tip focal, dual energy catheter first to be CE Marked for ventricular ablation New indication marks important milestone for ventricular arrhythmia patients as positive physician sentiment and global expansion for Sphere ‑ 9 continue Sphere VT U.S. pivotal trial enrollment underway GALWAY, Ireland, Aug. 6, 2026 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced an expanded CE Mark indication for the Affera™ Mapping and Ablation System with Sphere-9™ Catheter to treat ventricular arrhythmias, including ventricular tachycardia (VT) and premature ventricular complexes (PVCs). The Sphere-9 catheter is the first all-in-one mapping and ablation, large-tip focal, dual-energy catheter CE marked for ventricular ablation.
Medtronic (MDT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Advanced compute power, built on NVIDIA infrastructure, enables real-time decision support during the procedure FDA-cleared Instrument Exit Point (IEP), the first real-time AI application for robotic procedures from Medtronic, advances a precise, predictable, and personalized future for surgery GALWAY, Ireland, July 21, 2026 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, is presenting an early look at its next-generation compute platform for the operating room. Touch Surgery™ Aide — an AI-native surgical computing platform that powers the Touch Surgery™ ecosystem — enables real-time artificial intelligence during procedures.
GALWAY, Ireland, July 20, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results on Tuesday, September 1, 2026, for its first quarter of fiscal year 2027, which ends on Friday, July 31, 2026. A news release containing summary financial information will be issued at 5:45 a.m.
Acquisition adds category-defining SPRINT® PNS technology to Medtronic's pain therapy portfolio—the broadest in the industry.¹ GALWAY, Ireland, July 16, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it has completed its acquisition of SPR Therapeutics, Inc. (SPR), a privately held medical technology company and recognized leader in short-term, percutaneous peripheral nerve stimulation (PNS) therapies for chronic and acute pain management.
I initiate coverage on Medtronic, highlighting its status as a leading medtech name with premium margins. MDT offers an attractive diversification opportunity, combining consistent performance with accelerated revenue growth. The stock trades at undervalued levels, supporting a long-term bullish thesis and a defensive investment approach.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MDT and any ticker you trade — then tracks every position and per-strategy win rate.
